相关实验视频
Updated: Jun 4, 2025

05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.1K
阿斯特拉加索酸IV通过向TAK1来抑制内皮细胞前炎性激活来缓解动脉样硬化
Shuang Hua1, Han Zhang1, Jixu Li1
1Department of Cardiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
International immunopharmacology
|December 20, 2024
概括
阿斯特拉加索酸IV (AS-IV) 通过向内皮细胞中的TAK1,降低炎症和巨细胞活动来减少动脉样硬化. 这种天然化合物为心血管疾病提供了潜在的新疗法.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 动脉样硬化是一种慢性炎症性疾病,涉及内皮细胞激活和巨细胞招募.
- 阿斯特拉加索酸IV (AS-IV) 是来自Astragalus mongholicus的一种素,有望保护心血管.
研究的目的:
- 为了研究AS-IV的抗动脉样硬化作用.
- 阐明AS-IV作用的潜在分子机制.
主要方法:
- AS-IV口服给动脉样硬化小鼠;评估了斑块大小和血脂.
- 通过染色检查的内皮细胞激活和巨细胞透.
- 在体外研究中使用过孔检测,RT-qPCR和西白斑来评估AS-IV对内皮细胞和巨细胞的影响.
主要成果:
- 在不改变血液脂质的情况下,AS-IV剂量依赖地减少了动脉样硬化斑块大小.
- AS-IV抑制了内皮细胞的激活和巨细胞的透.
- 通过向TAK1和MAPK通路,AS-IV抑制了TNF-α诱导的内皮细胞激活和巨细胞迁移/粘附.
结论:
- AS-IV通过向内皮细胞中的TAK1来显示抗动脉样硬化性质.
- AS-IV 抑制了内皮细胞激活和随后的巨细胞招募,这是动脉样硬化的关键过程.
- AS-IV 提出了一种潜在的治疗策略,用于治疗动脉样硬化.
相关概念视频
Inflammation
52.5K
Overview
52.5K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
580
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
580
Adrenergic Antagonists: ɑ and β-Receptor Blockers
405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405

